The effects of bazedoxifene and estradiol on the bone mineral density and bone turnover markers in postmenopausal women

The effects of bazedoxifene and estradiol on the bone mineral density and bone turnover markers in postmenopausal women - The effects of bazedoxifene and estradiol on the bone mineral density and bone turnover markers in postmenopausal women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042068

Enrollment

1500

Registered

2021-06-14

Start date

2006-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia in postmenopausal woman

Interventions

12 months treatment with 20mg of bazedoxifene and 1mg of estradiol. Bone turnover markers after 3 months and bone mineral density after 12 months were each mesured.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: women within 3 years of onset of menopause whose TRACP-5b values were 420 mU/dL or higher

Exclusion criteria

Exclusion criteria: 1) past history of arterial/venous thromboembolism 2) past history of breast cancer

Design outcomes

Primary

Measure	Time frame
Changes in bone turnover markers after 3 months of treatment and lumbar spine BMD after 12 months of treatment	—

Countries

Japan

Contacts

Public ContactIkuko Ota Ikuko Ota

Kurashiki-Heisei Hospital Department of Gynecology

ikucom0195@gmail.com086-427-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026